A Phase 2 trial of a 6-week treatment schedule of neoadjuvant nivolumab and ipilimumab in operable MSI high or POLE exonuclease domain mutant colon cancer (CRC).

Biography

Professor  Agnieszka Michael MRCP PhD is a Clinical Academic at the University of Surrey and a Consultant Medical Oncologist  at the Royal Surrey NHS Foundation Trust . She has an interest in ovarian cancer and urological malignancies  and immunotherapy. She trained at St George's Hospital,  Royal Marsden  and Guy's and St Thomas' Hospital.  She was awarded a PhD for research in Cancer Immunotherapy by St George's, University of London, and continues to contribute to this field of research. Throughout her career Professor Michael has worked in the cancer clinical trials' field, including early phase studies with novel immunotherapy agents, gene therapy and cancer vaccines as well as international multi-centre phase III and IV studies, as a Chief investigator and a local Principal Investigator. Professor Michael is a Clinical Lead for National Ovarian Cancer Audit, as well as a Chair of Non-surgical Oncology in British Gynaecological Cancer Society. She also worked as a Director of Surrey Clinical Trials' Unit and Cancer Specialty Lead for NCRN Clinical Research Network  as well as clinical expert for NICE. 

See profile